DermTech (DMTK) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

DMTK Stock Forecast

DermTech stock forecast is as follows: an average price target of $15.00 (represents a 21639.13% upside from DMTK’s last price of $0.07) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

DMTK Price Target

The average price target for DermTech (DMTK) is $15.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 21639.13% upside from DMTK's last price of $0.07.

DMTK Analyst Ratings

Buy

According to 5 Wall Street analysts, DermTech's rating consensus is 'Buy'. The analyst rating breakdown for DMTK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

DermTech Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 15, 2022	-	BTIG	$15.00	$6.78	121.24%	21639.13%

Row per page

Go to

The latest DermTech stock forecast, released on Aug 15, 2022 by BTIG company, set a price target of $15.00, which represents a 121.24% increase from the stock price at the time of the forecast ($6.78), and a 21639.13% increase from DMTK last price ($0.07).

DermTech Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.07	$0.07	$0.07
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of DermTech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DermTech's last price of $0.07. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 19, 2024	Lake Street	Underperform	Underperform	Hold
Apr 19, 2024	Stephens	Buy	Buy	Hold
Apr 19, 2024	Lake Street	-	Hold	Downgrade
Nov 04, 2022	William Blair	-	Market Perform	Downgrade
Aug 17, 2022	Oppenheimer	Outperform	Outperform	Hold
Aug 15, 2022	BTIG	Buy	Buy	Hold
Apr 26, 2022	Zacks Investment Research	-	Sell	Downgrade

Row per page

Go to

DermTech's last stock rating was published by Lake Street on Apr 19, 2024. The company gave DMTK a "Underperform" rating, the same as its previous rate.

DermTech Financial Forecast

DermTech Revenue Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.48M	$2.99M	-	-	$3.72M	$3.17M	-	-	$2.52M	$2.12M	-	-	$1.56M	$1.59M
Avg Forecast	$7.30M	$6.70M	$5.80M	$5.60M	$4.45M	$4.48M	$4.28M	$4.23M	$4.20M	$4.19M	$3.95M	$3.94M	$4.04M	$3.90M	$3.70M	$3.43M	$2.55M	$4.66M	$4.82M	$3.75M	$3.33M	$3.42M	$2.85M	$2.11M	$1.82M	$1.14M	$500.00K	$1.00M	$1.08M
High Forecast	$7.30M	$6.70M	$5.80M	$5.60M	$4.45M	$4.48M	$4.28M	$4.23M	$4.20M	$4.19M	$3.95M	$3.94M	$4.19M	$3.90M	$3.70M	$3.43M	$2.55M	$4.66M	$4.82M	$3.75M	$3.33M	$3.42M	$2.85M	$2.11M	$1.82M	$1.14M	$500.00K	$1.00M	$1.08M
Low Forecast	$7.30M	$6.70M	$5.80M	$5.60M	$4.45M	$4.48M	$4.28M	$4.23M	$4.20M	$4.19M	$3.95M	$3.94M	$3.89M	$3.90M	$3.70M	$3.43M	$2.55M	$4.66M	$4.82M	$3.75M	$3.33M	$3.42M	$2.85M	$2.11M	$1.82M	$1.14M	$500.00K	$1.00M	$1.08M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.17%	-	-	0.99%	0.95%	-	-	1.20%	1.16%	-	-	1.56%	1.47%

DermTech's average Quarter revenue forecast for Jul 23 based on 2 analysts is $3.70M, with a low forecast of $3.70M, and a high forecast of $3.70M. DMTK's average Quarter revenue forecast represents a 6.36% increase compared to the company's last Quarter revenue of $3.48M (Mar 23).

DermTech EBITDA Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-32.04M	$-28.89M	-	-	$-29.40M	$-25.89M	-	-	$-11.53M	$-9.28M	-	-	$-6.94M	$-5.08M
Avg Forecast	$-7.30M	$-6.70M	$-5.80M	$-5.60M	$-4.45M	$-4.48M	$-4.28M	$-4.23M	$-4.20M	$-4.19M	$-3.95M	$-3.94M	$-4.04M	$-3.90M	$-3.70M	$-3.43M	$-2.55M	$-4.66M	$-4.82M	$-24.53M	$-3.33M	$-3.42M	$-2.85M	$-10.27M	$-1.82M	$-1.14M	$-500.00K	$-5.88M	$-1.08M
High Forecast	$-7.30M	$-6.70M	$-5.80M	$-5.60M	$-4.45M	$-4.48M	$-4.28M	$-4.23M	$-4.20M	$-4.19M	$-3.95M	$-3.94M	$-3.89M	$-3.90M	$-3.70M	$-3.43M	$-2.55M	$-4.66M	$-4.82M	$-19.62M	$-3.33M	$-3.42M	$-2.85M	$-8.22M	$-1.82M	$-1.14M	$-500.00K	$-4.71M	$-1.08M
Low Forecast	$-7.30M	$-6.70M	$-5.80M	$-5.60M	$-4.45M	$-4.48M	$-4.28M	$-4.23M	$-4.20M	$-4.19M	$-3.95M	$-3.94M	$-4.19M	$-3.90M	$-3.70M	$-3.43M	$-2.55M	$-4.66M	$-4.82M	$-29.44M	$-3.33M	$-3.42M	$-2.85M	$-12.32M	$-1.82M	$-1.14M	$-500.00K	$-7.06M	$-1.08M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.33%	11.32%	-	-	1.20%	7.76%	-	-	1.12%	5.09%	-	-	1.18%	4.71%

undefined analysts predict DMTK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than DermTech's previous annual EBITDA (undefined) of $NaN.

DermTech Net Income Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-30.50M	$-26.91M	-	-	$-29.94M	$-25.44M	-	-	$-15.07M	$-9.40M	-	-	$-7.00M	$-5.12M
Avg Forecast	$-9.02M	$-9.37M	$-9.37M	$-9.37M	$-17.70M	$-18.05M	$-18.05M	$-18.39M	$-17.70M	$-18.05M	$-18.05M	$-19.92M	$-19.61M	$-26.51M	$-33.76M	$-31.70M	$-33.42M	$-34.36M	$-35.19M	$-25.26M	$-25.74M	$-22.10M	$-18.51M	$-10.40M	$-18.45M	$-19.09M	$-12.84M	$-5.94M	$-13.88M
High Forecast	$-9.02M	$-9.37M	$-9.37M	$-9.37M	$-17.70M	$-18.05M	$-18.05M	$-18.39M	$-17.70M	$-18.05M	$-18.05M	$-19.92M	$-19.61M	$-26.51M	$-33.76M	$-31.70M	$-33.42M	$-34.36M	$-35.19M	$-20.21M	$-25.74M	$-22.10M	$-18.51M	$-8.32M	$-18.45M	$-19.09M	$-12.84M	$-4.75M	$-13.88M
Low Forecast	$-9.02M	$-9.37M	$-9.37M	$-9.37M	$-17.70M	$-18.05M	$-18.05M	$-18.39M	$-17.70M	$-18.05M	$-18.05M	$-19.92M	$-19.61M	$-26.51M	$-33.76M	$-31.70M	$-33.42M	$-34.36M	$-35.19M	$-30.32M	$-25.74M	$-22.10M	$-18.51M	$-12.48M	$-18.45M	$-19.09M	$-12.84M	$-7.12M	$-13.88M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.96%	0.81%	-	-	1.19%	0.99%	-	-	1.45%	0.51%	-	-	1.18%	0.37%

DermTech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DMTK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

DermTech SG&A Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$27.29M	$23.43M	-	-	$24.02M	$20.49M	-	-	$11.68M	$7.95M	-	-	$6.46M	$4.85M
Avg Forecast	$39.70M	$36.44M	$31.54M	$30.46M	$24.18M	$24.37M	$23.26M	$23.03M	$22.85M	$22.76M	$21.46M	$21.40M	$21.97M	$21.23M	$20.11M	$18.67M	$13.89M	$25.35M	$26.20M	$20.39M	$18.14M	$18.62M	$15.48M	$11.46M	$9.91M	$6.21M	$2.72M	$5.44M	$5.87M
High Forecast	$39.70M	$36.44M	$31.54M	$30.46M	$24.18M	$24.37M	$23.26M	$23.03M	$22.85M	$22.76M	$21.46M	$21.40M	$22.78M	$21.24M	$20.11M	$18.67M	$13.89M	$25.35M	$26.20M	$20.39M	$18.14M	$18.62M	$15.48M	$11.46M	$9.91M	$6.21M	$2.72M	$5.44M	$5.87M
Low Forecast	$39.70M	$36.44M	$31.54M	$30.46M	$24.18M	$24.37M	$23.26M	$23.03M	$22.85M	$22.76M	$21.46M	$21.40M	$21.16M	$21.23M	$20.11M	$18.67M	$13.89M	$25.35M	$26.20M	$20.39M	$18.14M	$18.62M	$15.48M	$11.46M	$9.91M	$6.21M	$2.72M	$5.44M	$5.87M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.46%	1.69%	-	-	1.18%	1.13%	-	-	1.02%	0.80%	-	-	1.19%	0.83%

DermTech's average Quarter SG&A projection for Jul 23 is $20.11M, based on 2 Wall Street analysts, with a range of $20.11M to $20.11M. The forecast indicates a -26.30% fall compared to DMTK last annual SG&A of $27.29M (Mar 23).

DermTech EPS Forecast

	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.00	$-0.89	-	-	$-1.00	$-0.86	-	-	$-0.68	$-0.35	-	-	$-0.53	$-0.39
Avg Forecast	$-0.26	$-0.27	$-0.27	$-0.27	$-0.51	$-0.52	$-0.52	$-0.53	$-0.51	$-0.52	$-0.52	$-0.57	$-0.57	$-0.76	$-0.97	$-0.91	$-0.96	$-0.99	$-1.01	$-0.89	$-0.74	$-0.64	$-0.53	$-0.43	$-0.53	$-0.55	$-0.37	$-0.46	$-0.40
High Forecast	$-0.26	$-0.27	$-0.27	$-0.27	$-0.51	$-0.52	$-0.52	$-0.53	$-0.51	$-0.52	$-0.52	$-0.57	$-0.57	$-0.76	$-0.97	$-0.91	$-0.96	$-0.99	$-1.01	$-0.89	$-0.74	$-0.64	$-0.53	$-0.43	$-0.53	$-0.55	$-0.37	$-0.46	$-0.40
Low Forecast	$-0.26	$-0.27	$-0.27	$-0.27	$-0.51	$-0.52	$-0.52	$-0.53	$-0.51	$-0.52	$-0.52	$-0.57	$-0.57	$-0.76	$-0.97	$-0.91	$-0.96	$-0.99	$-1.01	$-0.89	$-0.74	$-0.64	$-0.53	$-0.43	$-0.53	$-0.55	$-0.37	$-0.46	$-0.40
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.09%	0.92%	-	-	1.12%	1.16%	-	-	1.60%	0.66%	-	-	1.15%	0.97%

According to undefined Wall Street analysts, DermTech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DMTK previous annual EPS of $NaN (undefined).

DermTech Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DMTK	DermTech	$0.09	$15.00	16566.67%	Buy
OM	Outset Medical	$0.70	$11.00	1471.43%	Buy
FLGT	Fulgent Genetics	$16.71	$45.00	169.30%	Buy
CURI	CuriosityStream	$1.58	$2.50	58.23%	Buy
TMDX	TransMedics Group	$80.93	$126.75	56.62%	Buy
CLPT	ClearPoint Neuro	$10.74	$12.00	11.73%	Buy

DMTK Forecast FAQ

Is DermTech a good buy?

Yes, according to 5 Wall Street analysts, DermTech (DMTK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of DMTK's total ratings.

What is DMTK's price target?

DermTech (DMTK) average price target is $15 with a range of $15 to $15, implying a 21639.13% from its last price of $0.069. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will DermTech stock go up soon?

According to Wall Street analysts' prediction for DMTK stock, the company can go up by 21639.13% (from the last price of $0.069 to the average price target of $15), up by 21639.13% based on the highest stock price target, and up by 21639.13% based on the lowest stock price target.

Can DermTech stock reach $0?

DMTK's average twelve months analyst stock price target of $15 supports the claim that DermTech can reach $0 in the near future.

What are DermTech's analysts' financial forecasts?

DermTech's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $17.44M (high $17.44M, low $17.44M), average EBITDA is $-17.437M (high $-17.437M, low $-17.437M), average net income is $-72.19M (high $-72.19M, low $-72.19M), average SG&A $94.83M (high $94.83M, low $94.83M), and average EPS is $-2.08 (high $-2.08, low $-2.08). DMTK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $25.4M (high $25.4M, low $25.4M), average EBITDA is $-25.4M (high $-25.4M, low $-25.4M), average net income is $-37.136M (high $-37.136M, low $-37.136M), average SG&A $138.14M (high $138.14M, low $138.14M), and average EPS is $-1.07 (high $-1.07, low $-1.07).

Did the DMTK's actual financial results beat the analysts' financial forecasts?

Based on DermTech's last annual report (Dec 2022), the company's revenue was $14.52M, which missed the average analysts forecast of $15.78M by -8.00%. Apple's EBITDA was $-118M, beating the average prediction of $-36.562M by 223.58%. The company's net income was $-114M, missing the average estimation of $-128M by -11.32%. Apple's SG&A was $94.76M, beating the average forecast of $85.83M by 10.41%. Lastly, the company's EPS was $-3.79, missing the average prediction of $-3.857 by -1.74%. In terms of the last quarterly report (Mar 2023), DermTech's revenue was $3.48M, beating the average analysts' forecast of $3.43M by 1.26%. The company's EBITDA was $-32.038M, beating the average prediction of $-3.434M by 833.08%. DermTech's net income was $-30.495M, missing the average estimation of $-31.698M by -3.80%. The company's SG&A was $27.29M, beating the average forecast of $18.67M by 46.15%. Lastly, the company's EPS was $-1, beating the average prediction of $-0.913 by 9.49%